About Michael Shi

Dr. Shi was the Global Program Clinical Head at Novartis Pharmaceuticals Corp. Dr. Shi provided key leadership role in the clinical development of multiple novel oncology/hematology products, including Tabrecta (capmatinib, INC280), Zykadia (ceritinib, LDK378), Adakveo (crizanlizumab, SEG101). He also worked as Program Director of Genetics Variation at NIH. Dr. Shi received a Ph.D. in Molecular Pharmacology & Toxicology from the University of Southern California and conducted a fellowship at Harvard Medical School.